NEURL4 inhibitors are a class of chemical compounds designed to specifically target and block the activity of NEURL4, a crucial enzyme in cellular processes. NEURL4, short for Neuralized E3 Ubiquitin Protein Ligase 4, plays a pivotal role in regulating the ubiquitin-proteasome system, which is responsible for the targeted degradation of proteins within the cell. This class of inhibitors is primarily utilized in scientific research and drug discovery efforts to better understand the biological functions associated with NEURL4 and its downstream effects on cellular homeostasis.
NEURL4 inhibitors involves binding to the active site of NEURL4, preventing it from performing its ubiquitin ligase function. This, in turn, disrupts the ubiquitination and subsequent degradation of specific target proteins, leading to the accumulation of these proteins within the cell. Researchers employ NEURL4 inhibitors to elucidate the consequences of inhibiting NEURL4-mediated protein degradation, enabling the study of various cellular pathways and functions. By selectively inhibiting NEURL4, scientists can investigate the impact on protein stability, cellular signaling, and protein-protein interactions. This class of inhibitors plays a vital role in advancing our knowledge of cellular biology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Proteasome inhibitor that prevents the degradation of ubiquitinated proteins, thus indirectly affecting NEURL4 activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that can stabilize proteins targeted by NEURL4 for degradation. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Specific inhibitor of the proteasome that would increase levels of proteins ubiquitinated by NEURL4. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
Irreversible proteasome inhibitor, leading to accumulation of substrates of E3 ligases like NEURL4. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
Inhibits NEDD8-activating enzyme, affecting ubiquitin-like protein neddylation and can indirectly affect NEURL4 activity. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
A natural product that selectively inhibits proteasome activity, thereby influencing NEURL4 function. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
A small-molecule proteasome inhibitor, which can indirectly affect the function of NEURL4. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
An orally bioavailable proteasome inhibitor that can impact the pathway in which NEURL4 is involved. | ||||||
Delanzomib, free base | 847499-27-8 | sc-396774 sc-396774A | 5 mg 10 mg | $160.00 $300.00 | ||
A proteasome inhibitor that might alter the degradation pathway involving NEURL4. | ||||||
Ubiquitin E1 Inhibitor, PYR-41 | 418805-02-4 | sc-358737 | 25 mg | $360.00 | 4 | |
An inhibitor of ubiquitin activating enzyme E1, which could indirectly affect NEURL4's role in ubiquitination. | ||||||